Phaseline

Companies › Vera Therapeutics

Vera Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 3; Genitourinary; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Atacicept
Tumor necrosis factor ligand superfamily member 13B inhibitor; Tumor necrosis factor ligand superfamily member 13 inhibitor
TNFSF13B, TNFSF13Phase 3IgA Nephropathy; IgA Nephropathy (IgAN); pMNSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07020923AtaciceptPhase 2IgA Nephropathy (IgAN)GenitourinarySep 2027
NCT06983028AtaciceptPhase 2pMNGenitourinaryNov 2027
NCT04716231AtaciceptPhase 3IgA NephropathyGenitourinaryJul 2028

From the company's SEC filings

Cash and short-term investments of $384m on 2026-09-30; operating cash outflow about $411m a year; runway about 11 months at that burn, to Sep 2027; 0 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Specialist investors

Held by 13 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

TNFSF13B (1) TNFSF13 (1)

Companies with the same targets

GSK Zura Bio Luminary Therapeutics Otsuka

Companies built like this

Humacyte Prokidney Genexine Vantive Health Cerium Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.